TABLE 1

Subject Demographic Features

ProQuad + Placebo (Group 1) (N = 399)M-M-RII + Placebo (Group 2) (N = 205)M-M-RII + Varivax (Group 3) (N = 195)Total (N = 799)
Gender, no. (%)
    Male208 (52.1)100 (48.8)118 (60.5)426 (53.3)
    Female191 (47.9)105 (51.2)77 (39.5)373 (46.7)
Age, y
    Mean4.34.34.34.3
    SD0.50.50.50.5
    Median4.04.04.04.0
    Range4–64–64–64–6
        Male4–64–64–64–6
        Female4–64–54–54–6
Race, no. (%)
    Black49 (12.3)19 (9.3)25 (12.8)93 (11.6)
    Asian/Pacific8 (2.0)5 (2.4)3 (1.5)16 (2.0)
    White313 (78.4)162 (79.0)153 (78.5)628 (78.6)
    Hispanic15 (3.8)10 (4.9)7 (3.6)32 (4.0)
    Other14 (3.5)9 (4.4)7 (3.6)30 (3.8)
Primary vaccination information for M-M-RII
    Age at primary vaccination, mean (95% CI), y1.19 (1.16–1.22)1.19 (1.15–1.23)1.18 (1.15–1.21)1.19 (1.17–1.21)
    Interval, mean (95% CI), ya3.37 (3.32–3.41)3.36 (3.30–3.42)3.40 (3.34–3.45)3.37 (3.34–3.40)
Primary vaccination information for Varivax
    Age at primary vaccination, mean (95% CI), y1.37 (1.32–1.43)1.39 (1.31–1.46)1.45 (1.37–1.53)1.40 (1.36–1.43)
    Interval, mean (95% CI), ya3.19 (3.13–3.24)NA3.13 (3.04–3.21)3.17 (3.12–3.21)
  • N indicates the total number of subjects vaccinated; NA, not applicable.

  • a Time elapsed between primary vaccination and study vaccination.